You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

An Endorsement of the 2018 Guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline

Version: N/A ID: GL END 3-22 Apr 2020
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Authors:
H. Lukka, J. Brown, C. Catton, B. Shayegan, the Hypofractionated Radiation Therapy for Prostate Cancer Guideline Development Group

Abstract – Guideline Objective:

The objectives of this guideline are to assess the advantages of hypofractionated radiation therapy compared to conventional fractionation in terms of prostate control, toxicity, and quality of life. Our recommendations are based on the 2018 Guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline.

Abstract – Patient Population:

Men with localized prostate cancer.

Abstract – Intended Guideline Users:

The guideline document will support providers in recommending the most optimal radiation therapy schedules to their patients.

Abstract – Research Questions:

The objectives of this guideline endorsement are to assess the advantages of hypofractionated radiation therapy com:pared to conventional fractionation in terms of prostate control, toxicity, and quality of life. With respect to the ASTRO guidelines we assessed the following:

  1. Does the Working Group agree with the interpretation of the evidence and the justification of the original recommendation?
  2. Are modifications required to align with the Ontario context?
  3. Is it likely there is new, unidentified evidence that would call into question the recommendation?
  4. Are statements of qualification/clarification to the recommendation required?
pdf download Full Report (PDF) (315.62 KB)